All News Celcuity Inc.

Equities

CELC

US15102K1007

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
17.84 ^USD	+0.96%		+11.15%	+22.44%

Mar. 29	Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement	CI
Mar. 28	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences	Apr. 04	AQ
Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement	Mar. 29	CI
Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	Mar. 28	MT
Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating	Mar. 28	MT
Transcript : Celcuity Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
Celcuity Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 27	AQ
Celcuity Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call	Mar. 20	AQ
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024	Mar. 06	AQ
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference	Feb. 28	AQ
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	Feb. 22	AQ
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	Feb. 22	CI
Stifel Initiates Celcuity With Buy Rating, Price Target is $40	Feb. 22	MT
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	Feb. 20	AQ
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	Feb. 20	CI
HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target	Dec. 08	MT
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	Dec. 06	AQ
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	Dec. 06	CI
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium	Dec. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Celcuity Inc.

Equities

CELC

US15102K1007

All News

Filters